Novartis AG (NVSEF)
OTCMKTS
· Delayed Price · Currency is USD
109.60
0.00 (0.00%)
Oct 29, 2024, 4:00 PM EDT
Novartis AG Revenue
Novartis AG had revenue of $13.17B in the quarter ending September 30, 2024, with 8.93% growth. This brings the company's revenue in the last twelve months to $49.94B, up 8.92% year-over-year. In the year 2023, Novartis AG had annual revenue of $46.66B with 7.36% growth.
Revenue (ttm)
49.94B
Revenue Growth
+8.92%
P/S Ratio
n/a
Revenue / Employee
656.61K
Employees
76,057
Market Cap
220.13B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 46.66B | 3.20B | 7.36% |
| Dec 31, 2022 | 43.46B | -513.00M | -1.17% |
| Dec 31, 2021 | 43.97B | -5.92B | -11.87% |
| Dec 31, 2020 | 49.90B | 1.22B | 2.51% |
| Dec 31, 2019 | 48.68B | 2.58B | 5.59% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sandoz Group AG | 10.11B |
| Telix Pharmaceuticals Limited | 430.80M |
| Elekta AB (publ) | 1.69B |
| Ryman Healthcare Limited | 411.39M |
| Verano Holdings Corp. | 920.97M |
| Vireo Growth Inc. | 98.04M |
| Medexus Pharmaceuticals Inc. | 108.78M |
Novartis AG News
- 1 day ago - Novartis Scemblix® FDA approved in newly diagnosed CML, offering superior efficacy, and favorable safety and tolerability profile - GlobeNewsWire
- 1 day ago - Novartis AG (NVS) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 1 day ago - Novartis Posts Results Above Estimates, Raises Outlook - Investopedia
- 1 day ago - Novartis Lifts Guidance Again After Key Drugs Help Results - WSJ
- 2 days ago - Novartis: we are exploring obesity drugs but other areas provide growth for years - Reuters
- 2 days ago - Novartis lifts 2024 guidance for 3rd time on wider use of its drugs - Reuters
- 2 days ago - Novartis continues strong momentum in Q3 with 10% sales growth, 20% core operating income growth, and important innovation milestones; raises FY 2024 guidance - GlobeNewsWire
- 2 days ago - Monte Rosa: Novartis Deal Bolsters MGD Platform With Flush Of Cash - Seeking Alpha